Rapid optimization and prototyping for therapeutic antibody-like molecules.

MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)

Rapid optimization and prototyping for therapeutic antibody-like molecules.

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.

Targeting HER3 for cancer treatment: a new horizon for an old target.

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.

Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.

Mechanisms of resistance to ErbB-targeted cancer therapeutics.

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.

Understanding the biology of HER3 receptor as a therapeutic target in human cancer.

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.

Therapeutic Targeting of the IGF Axis.

Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas.

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.

Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.

The insulin and insulin-like growth factor receptor family in neoplasia: an update.

IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.


ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.